Winner of the European EIC Accelerator program, EVerZom accelerates the industrialization of its exosome bioproduction platform for regenerative medicine
Paris, 18 November 2021 — EVerZom, a biopharmaceutical company specialized in the biomanufacturing of extracellular vesicles (or exosomes), announced today that it has obtained non-dilutive funding of €2.5 million as the winner of the European EIC Accelerator competition (Horizon Europe). This funding will enable the company to transfer its extracellular vesicle biomanufacturing technology for a first clinical grade batch production and to accelerate the scale-up of its production capabilities by developing a process compatible with clinical Phase 2/3 for the pharmaceutical industry. [Read more…]
Saint-Gobain Life Sciences and denovoMATRIX Announce Collaboration to Optimize New Product Development
DRESDEN, Germany, 9 November, 2021 / BioInformant / — denovoMATRIX GmbH and Saint-Gobain Life Sciences have entered into a Master Service Agreement focused on optimizing the performance of new products in development for adherent cell culture and harvest for autologous therapies. The relationship will further explore the synergy of consumable products from both parties and their positive effects for the therapeutic market. [Read more…]
Ncardia Secures $60+ Million to Enhance and Expand Leading iPSC Offerings
Ncardia forms strategic partnership with Kiniciti to build GMP capabilities to support iPSC cell therapy platforms and human cell-based in vitro discovery services
November 16, 2021, GOSSELIES, Belgium & NEW YORK — Ncardia, a leader in developing stem cell-based solutions for drug discovery and cell therapy, announced that it has secured more than $60 million in capital through a strategic partnership with Kiniciti, a U.S.-based investment platform focused on strengthening the cell and gene therapy ecosystem worldwide. [Read more…]
Shoreline Biosciences Announces $140M Financing To Advance Pipeline of iPSC-based Cell Immunotherapies
-
Shoreline Biosciences Announces $140M Financing To Advance Its Growing Pipeline Of Next Generation Cell Immunotherapies
-
Financing accelerates the growth of Shoreline’s pipeline of iPSC-based cell immunotherapies for the treatment of seriously ill patients and enables the buildout of smart manufacturing capabilities.
- « Previous Page
- 1
- …
- 37
- 38
- 39
- 40
- 41
- …
- 96
- Next Page »